top of page
Interview: Keeping "sight" of tomorrow.
A conversation with Perry Sternberg, CEO Sydnexis.
Sydnexis is in FDA review to become the first approved drug therapy for pediatric myopia in the US
bottom of page
Interview: Keeping "sight" of tomorrow.
A conversation with Perry Sternberg, CEO Sydnexis.
Sydnexis is in FDA review to become the first approved drug therapy for pediatric myopia in the US